Liposome Technology Inc. announced Monday that it has begunselling Amphocil on a named-patient basis in Israel.

LTI (NASDAQ:LTIZ) of Menlo Park, Calif., is already sellingAmphocil, its lipid-based formulation of amphotericin B fortreating systemic fungal infections, in Austria and Ireland on anamed-patient basis.

LTI is currently conducting multicenter Phase III clinical trialsin the U.S. and Europe on Amphocil, including two open-labeltrials and one double-blind study, and has already filed formarketing authorization approval (MAA) in the UnitedKingdom and Ireland.

(c) 1997 American Health Consultants. All rights reserved.

No Comments